Reckitt Raises Guidance On Adams Performance, Marketing Momentum
This article was originally published in The Tan Sheet
Executive Summary
Reckitt Benckiser raises its 2008 sales targets based on the performance of brands added with its acquisition of Adams Respiratory Therapeutics early this year and heavy marketing investment in its latest quarter
You may also be interested in...
OTC Innovation Requires Stretching Focus Beyond New Molecules
Complex regulatory schemes, long lead times to launch OTC products and private label competition impede new product development
Reckitt Benckiser/Adams deal wraps
U.K.-based Reckitt Benckiser completes the acquisition of Adams Respiratory Therapeutics, makers of Mucinex-brand cough/cold products, through a cash tender offer "followed by a short-form merger of its indirect wholly owned subsidiary, Twickenham, with and into Adams," the firm announces Jan. 30. Reckitt announced plans to pay remaining Adams shareholders $60 per share, the same price paid in the tender offer made in December 2007, the firm says (1"The Tan Sheet" Jan. 28, 2008, In Brief)...
Adams Faces Another Mucinex Challenge, Prepares For Product Launches
Adams Respiratory Therapeutics has been hit with another patent claim challenge involving its Mucinex line as it prepares to launch line extensions for its blockbuster brand and other new products in time for the cough/cold season